[NN3201]
[AACR Poster] NN3201, A novel c-Kit targeting ADC, exhibits robust preclinical anti-tumor efficacy in SCLC and GIST models (2024)
[AACR Poster] In vivo efficacy and preclinical safety profile of NN3201, an anti-cKIT antibody-drug conjugate, for treating SCLC and AML (2023)
[AACR poster] An Optimized Preclinical Antibody-Drug Conjugate Against Cancers with cKIT Overexpression or Activating Mutations (2022)